Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24709289 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBSIGMAR1LMNARAB9A | |
| Bromide SCHEMBL31141380 | 0.78 | SMN1; SMN2 (0.49) | SMN1; SMN2POLBSIGMAR1LMNARAB9A | |
| SCHEMBL8924899 | 0.75 | DRD3 (0.60) | SMN1; SMN2POLBSIGMAR1LMNADRD3 | |
| SCHEMBL2584872 | 0.75 | ALDH1A1 (0.55) | SMN1; SMN2POLBLMNARAB9ANPC1 | |
| SCHEMBL2582158 | 0.74 | ALDH1A1 (0.56) | SIGMAR1NPC1HTTKMT2A | |
| SCHEMBL2583741 | 0.74 | SIGMAR1 (0.54) | SMN1; SMN2POLBSIGMAR1LMNARAB9A | |
| SCHEMBL11730441 | 0.74 | MAPT (0.65) | SMN1; SMN2POLBSIGMAR1MAPTDRD3 | |
| SCHEMBL6795896 | 0.73 | POLB (0.96) | SMN1; SMN2POLBSIGMAR1HTTCYP1A2 | |
| SCHEMBL13293705 | 0.72 | POLB (1.00) | SMN1; SMN2POLBSIGMAR1HTTCYP1A2 | |
| SCHEMBL24023501 | 0.72 | POLB (1.00) | SMN1; SMN2POLBSIGMAR1HTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048877-B2 | Guanidine derivatives and their medical use | NEUROSEARCH A/S (DK) | 2011-11-01 | — | — | US | claimed |
| US-20090099208-A1 | NOVEL GUANIDINE DERIVATIVES AND THEIR MEDICAL USE | ACESION PHARMA APS (DK) | 2009-04-16 | — | — | US | claimed |
| US-8048877-B2 | Guanidine derivatives and their medical use | NEUROSEARCH A/S (DK) | 2011-11-01 | — | — | US | disclosed |
| US-20090099208-A1 | NOVEL GUANIDINE DERIVATIVES AND THEIR MEDICAL USE | ACESION PHARMA APS (DK) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099208-A1 | NOVEL GUANIDINE DERIVATIVES AND THEIR MEDICAL USE | KCNN2, KCNN1, KCNN3 | SMN1; SMN2 1464/4885POLB 4457/4885SIGMAR1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.